Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group.

This article reports on a large longitudinal study, begun in 1993, of the natural history of human papillomavirus (HPV) infection and cervical neoplasia in a population of low-income women in São Paulo, Brazil, a city with one of the highest risks worldwide for cervical cancer. Known as the Ludwig-McGill cohort study, the epidemiological investigation focuses on persistent infection with oncogenic HPV types as the precursor event leading to cervical neoplasia. The objectives of this study are to: 1) study the epidemiology of persistent cervical HPV infection in asymptomatic women, 2) investigate whether persistent HPV infection increases risk of low-grade and high-grade cervical lesions, 3) search for determinants of persistent HPV infection, 4) search for molecular variants of HPV that may be associated with an increased risk of lesions, 5) investigate whether viral burden is correlated with persistent infections and with lesion risk, 6) study the antibody response to HPV as a predictor of persistence and lesion progression, and 7) examine the role of HLA typing and codon 72 p53 gene polymorphism in mediating HPV persistence and lesion severity. The study accrued 2,528 female subjects through March 1997. Subjects were followed up every 4 months in the first year, with twice-yearly return visits to take place in subsequent years. Participants undergo a questionnaire-based interview, have a cervical specimen taken for Pap cytology and HPV testing, and have a blood sample drawn for HPV antibody testing. A cervicography is performed once in the first year and every two years thereafter. In this article we describe the design and methods of the study, provide baseline cohort characteristics, and present a preliminary assessment of the prognostic value of baseline HPV status.

[1]  J. Bodmer,et al.  Nomenclature for factors of the HLA System, 1996. , 1997, Human immunology.

[2]  Andrew J. G. Simpson,et al.  Low stringency-PCR (LS-PCR) allows entirely internally standardized DNA quantitation , 1995, Nucleic Acids Res..

[3]  A. Reingold,et al.  Genital human papillomavirus infection in female university students as determined by a PCR‐based method , 1991, JAMA.

[4]  C. Brown,et al.  The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. , 1990, Acta cytologica.

[5]  A. Štafl,et al.  Cervicography: a new method for cervical cancer detection. , 1981, American journal of obstetrics and gynecology.

[6]  T. Rohan,et al.  Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. , 1999, Journal of the National Cancer Institute.

[7]  David R. Scott,et al.  p53 polymorphism and risk of cervical cancer , 1998, Nature.

[8]  H. Johnsen,et al.  p53 polymorphism and risk of cervical cancer , 1998, Nature.

[9]  E. Franco,et al.  Molecular variant analysis as an epidemiological tool to study persistence of cervical human papillomavirus infection. , 1994, Journal of the National Cancer Institute.

[10]  D. Lowy,et al.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles , 1993, Journal of virology.

[11]  David R. Scott,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[12]  A. Halpern,et al.  Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments , 1995, Journal of virology.

[13]  D. Lowy,et al.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.

[14]  J. Walboomers,et al.  General primer‐mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas , 1990, International journal of cancer.

[15]  C. Peyton,et al.  Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. , 1994, The Journal of infectious diseases.

[16]  L. Mango,et al.  Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. , 1997, Revista panamericana de salud publica = Pan American journal of public health.

[17]  H. Bernard,et al.  Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree , 1991, Journal of clinical microbiology.

[18]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[19]  Diane Soloman,et al.  The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses: Developed and approved at the national cancer institute workshop in Bethesda, MD, December 12–13, 1988 , 1989, Diagnostic cytopathology.

[20]  H. Pfister,et al.  Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups , 1993, Journal of virology.

[21]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.